secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001367644-23-000152
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q2 revenue $338M beats guidance; net loss $261M on $307M impairment; FY guidance cut
--------------------------------------------------------------------------------

- Q2 total revenues $338M vs. prior guidance range; net loss $261M ($5.15 diluted EPS) on $307M CDMO asset impairment.
- Adjusted EBITDA of $56M improved from $(29)M a year ago; adjusted net loss per share $1.06.
- FY 2023 revenue guidance revised to $1.0-1.1B (from $1.1-1.2B); adjusted EBITDA cut to $50-100M from $100-150M.
- CEO transition: Haywood Miller appointed interim CEO after Robert Kramer retired; FDA approved CYFENDUS anthrax vaccine.
- Sale of travel health business to Bavarian Nordic for up to $380M closed; 10-year BARDA contract for Ebanga Ebola treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/0001367644-23-000152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000152/ebs-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer